Open Journal of Molecular and Integrative Physiology
Vol.7 No.1(2017), Paper ID 74454, 23
pages
DOI:10.4236/ojmip.2017.71001
The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size
Ikuo Inoue, Ryo Kubota, Shohan Yanagi, Masumi Akita, Takanari Nakano, Shigehiro Katayama, Akira Shimada, Mistuhiko Noda
Department of Endocrinology and Diabetology, Saitama Medical University, Saitama, Japan
Department of Health Sciences, Saitama Prefectural University, Saitama, Japan
Research and Development Department, Advanced Materials Development Sector, Tokyo Metropolitan Industrial Technology Research Institute, Tokyo, Japan
Division of Morphological Science, Biomedical Research Center, Saitama Medical University, Saitama, Japan
Department of Biochemistry, Saitama Medical University, Saitama, Japan
Department of Endocrinology and Diabetology, Saitama Medical University, Saitama, Japan
Department of Endocrinology and Diabetology, Saitama Medical University, Saitama, Japan
Department of Endocrinology and Diabetology, Saitama Medical University, Saitama, Japan
Copyright © 2017 Ikuo Inoue, Ryo Kubota, Shohan Yanagi, Masumi Akita, Takanari Nakano, Shigehiro Katayama, Akira Shimada, Mistuhiko Noda et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Inoue, I. , Kubota, R. , Yanagi, S. , Akita, M. , Nakano, T. , Katayama, S. , Shimada, A. and Noda, M. (2017) The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size.
Open Journal of Molecular and Integrative Physiology,
7, 1-23. doi:
10.4236/ojmip.2017.71001.